Jason Stadanlick
Principal Scientist Cabaletta Bio
Dr. Jason Stadanlick joined Cabaletta Bio in August 2021 and is currently a Principal Scientist in the Translational Medicine Group. In his role, Jason is responsible for reviewing all translational data from the Rese-cel phase 1/2 studies. As an Associate Principal Scientist, Jason oversaw the development and qualification of all cellular and serum cytokine characterization assays in the translational medicine group. Prior to joining Cabaletta, Dr. Stadanlick was a scientist at Spark Therapeutics, where he led research efforts to evaluate the immunogenicity of AAV-based delivery platforms. Before that, Dr. Stadanlick worked for the Department of Surgery at UPENN characterizing the role of myeloid cells in non-small cell lung tumors. He is a scientist with 15 years of industry and academic experience in adoptive immunotherapy, translational research, autoimmunity, and tumor immunology. Dr. Stadanlick received his Ph.D. from the University of Pennsylvania and completed a postdoctoral fellowship at the Fox Chase Cancer Center. He is currently a member of the American Association of Immunologists and American Society of Cell and Gene Therapy and has authored or contributed to 25 peer-reviewed original and review articles.
Seminars
Join this session for a candid conversation with experts pursuing the reality of of-the-shelf cell therapies:
- Discussing the advantages of using allogeneic approaches over autologous approaches to make immune resetting scalable for large autoimmune patient populations
- Focusing on necessary gene-editing strategies and conditioning regimens to eliminate the risk of graft vs host disease and other safety concerns
- Deep diving into current indications being explored for allogeneic cell therapy
- Discussing the emerging clinical data showing deep, sustained B-cell depletion in Lupus patients
- Exploring whether depth of depletion translates into long-term, drug-free remission that has been unattainable with conventional treatments
- Identifying signatures in the repopulating B-cell and T-cell compartments that predict durable remission and guide the regulatory pathway for a curative therapy
